CHINA China's inactivated COVID-19 vaccine shows promising results in two phase trials

CHINA

China's inactivated COVID-19 vaccine shows promising results in two phase trials

Xinhua

16:58, June 17, 2020

f21410fdd0404e879e4fb65b08f2870d.png

File photo

BEIJING, June 17 (Xinhua) -- China has unveiled the results of the phase 1 and phase 2 clinical trials of an inactivated COVID-19 vaccine candidate, which shows promising results in both safety and efficacy, according to the China National Pharmaceutical Group (Sinopharm).

The vaccine, developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to Sinopharm, involved 1,120 volunteers aged between 18 and 59 in its clinical trials, which started on April 12.

The results revealed a good safety record, with no cases of severe adverse effects found in the clinical trials. The vaccine receivers inoculated with two injections in different procedures and doses have all produced high titers of antibodies.

For those receiving two middle-dose injections at intervals of 14 days and 21 days, the seroconversion rate of neutralizing antibodies reached 97.6 percent. For those receiving two middle-dose injections at an interval of 28 days, the seroconversion rate of neutralizing antibodies reached 100 percent.

The CNBG is actively promoting overseas cooperation in the phase 3 clinical trial of the vaccine and has secured the intention of cooperation of several companies and research institutions from other countries.

The company has also built a production workshop with high-level biosafety, which could help ensure the supply of vaccines for emergency use.


Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue